References
- Awaad Y, Rizk T, Siddiqui I, Roosen N, McIntosh K, Waines GM. Complications of intrathecal baclofen pump: prevention and cure. ISRN Neurol. 2012, 575168 (2012).
- Di Marzo V. The endocannabinoid system for the development of new drugs for spasticity. Drugs Fut. 32(4), 351–361 (2007).
- Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32(5), 451–459 (2010).
- Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18(9), 1122–1131 (2011).
- Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J. Neurol. 260(1), 285–295 (2013).
- Schoedel KA, Chen N, Hilliard A et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum. Psychopharmacol. 26(3), 224–236 (2011).
- García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev. Neurother. 13(3 Suppl. 1), 9–13 (2013).
- Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev. Neurother. 13(3 Suppl. 1), 15–19 (2013).
- Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 439–441 (2012).
Website
- Gold R. DGN / KKNMS Leitlinie zur Diagnose und Therapie der MS – Online Version, 12 April 2012. www.dmsg.de/dokumentearchiv/dgnkknms_msll_20120412_final.pdf